CSIMarket
 
Agenus Inc  (NASDAQ: AGEN)
Other Ticker:  
 
 
Price: $3.5000 $0.04 1.156%
Day's High: $3.525 Week Perf: 0.00
Day's Low: $ 3.29 30 Day Perf: 11.29 %
Volume (M): 207 52 Wk High: $ 19.69
Volume (M$): $ 725 52 Wk Avg: $7.91
Open: $3.47 52 Wk Low: $2.50



 Market Capitalization (Millions $) 75
 Shares Outstanding (Millions) 22
 Employees 114
 Revenues (TTM) (Millions $) 160
 Net Income (TTM) (Millions $) -234
 Cash Flow (TTM) (Millions $) -62
 Capital Exp. (TTM) (Millions $) 1

Agenus Inc
Agenus Inc. is a biotechnology company based in Lexington, Massachusetts. The company is focused on the discovery, development, and commercialization of immune-based therapies for the treatment of cancer and other diseases. Agenus utilizes its proprietary technologies to develop novel antibodies, vaccines, and adjuvants to activate the immune system against cancer cells. The company's product pipeline includes both clinical and pre-clinical stage candidates targeting various types of cancer. Agenus also collaborates with other pharmaceutical companies to advance its immunotherapy programs.


   Company Address: 3 Forbes Road Lexington 2421 MA
   Company Phone Number: 674-4400   Stock Exchange / Ticker: NASDAQ AGEN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP   -7.02%    
AMGN        1.17% 
BLUE        15.26% 
EXEL        3.02% 
GILD        10.33% 
MRNA   -2.09%    
• View Complete Report
   



Business Update

Agenus Inc. Secures $22 Million Mortgage to Support Operational Realignment and Financial Stability,

Published Wed, Nov 27 2024 1:47 PM UTC

Agenus Inc. Secures a $22 Million Mortgage to Propel Strategic Growth Amid Operational Realignment In an ambitious move aimed at bolstering its financial footing, Agenus Inc. (Nasdaq: AGEN), a biopharmaceutical company specializing in immuno-oncology, has successfully secured a $22 million non-amortizing mortgage. This significant funding is backed by the company?s state-of-...

Business Update

Navigating Challenges How Agenus Inc. Is Reshaping the Landscape of Cancer Immunotherapy,

Published Tue, Nov 12 2024 3:36 PM UTC

Innovations Amidst Challenges: Agenus Inc. Reports on Strategic Advancements in Cancer Immunotherapy In an era where the fight against cancer has prompted remarkable advancements, Agenus Inc. (Nasdaq: AGEN) stands out with its latest developments in immuno-oncology. On the heels of its third-quarter financial results for 2024, the company is not only reformulating its strat...

Business Update

Agenus on the Rise Trailblazing Immunotherapy Innovations Set Stage for Breakthroughs in Cancer Treatment and Unprece...

Published Thu, Nov 7 2024 4:36 PM UTC

Unlocking New Horizons in Cancer Treatment: Agenus? Promising Advances in ImmunotherapyIn an era defined by groundbreaking medical innovations, Agenus Inc., a pioneering leader in immunological cancer therapy, is making significant strides toward transforming the landscape of cancer treatment. Recently, the company announced its participation in the Society for Immunotherap...

Announcement

Agenus Inc. Faces Class Action Lawsuit as Financial Struggles Deepen with $283 Million Loss,

Published Mon, Sep 30 2024 5:52 PM UTC

The biotechnology sector continues to experience volatility, and particularly in the case of Agenus Inc. (NASDAQ: AGEN), financial hardship has prompted significant concerns among investors. Recent reports have highlighted that the company s cumulative net loss reached a staggering $283 million as of the third quarter of 2023. This has resulted in a troubling negative return...

Business Update

Abstract The development of novel immunotherapies has transformed the landscape of cancer treatment...

Published Wed, Aug 7 2024 5:47 PM UTC

The Efficacy of Botensilimab in Treatment-Resistant Cancers: Insights from Recent Research Abstract The development of novel immunotherapies has transformed the landscape of cancer treatment, particularly for advanced and treatment-resistant malignancies. One such promising candidate is botensilimab, a multifunctional anti-CTLA-4 antibody being investigated by Agenus Inc....







Agenus Inc's Segments
Other services    1.81 % of total Revenue
Non-cash royalty revenue    98.19 % of total Revenue
United States    98.19 % of total Revenue
United States Non-cash royalty revenue    98.19 % of total Revenue
Rest of World    1.81 % of total Revenue
Rest of World Other services    1.81 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com